Hepatocellular Carcinoma - KOL Insight

Explore the evolving landscape of hepatocellular carcinoma (HCC) treatment. Leading KOLs provide insights on the consolidation of Roche's Tecentriq (atezolizumab) plus Avastin (bevacizumab) as the first-line treatment for unresectable HCC, the rising use of AstraZeneca's Imfinzi (durvalumab) plus Imjudo (tremelimumab) for patients contraindicated for Avastin, and the potential of Bristol Myers Squibb's Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment. Gain an understanding of the emerging role of novel therapies and the implications for clinical practice and drug development.

Key questions answered:

• How do KOLs use Roche's Tecentriq (atezolizumab) plus Avastin (bevacizumab) in HCC? Have KOLs used the combination in the adjuvant setting since the data from IMbrave050?
• Which agents do the experts prefer to use after Tecentriq plus Avastin progression or in patients unsuitable for the combination?
• What has the uptake of AstraZeneca's Imfinzi (durvalumab) and Imjudo (tremelimumab) been like since its approval? How do KOLs place it in the treatment algorithm?
• How do KOLs use TKIs Nexavar (sorafenib; Bayer) and Lenvima (lenvatinib; Eisai/Merck & Co.), and how are they placed in the treatment algorithm?
• What do KOLs think of agents such as Stivarga (regorafenib; Bayer), Cabometyx (cabozantinib; Exelixis/Ipsen) and Cyramza (ramucirumab; Eli Lilly) and their relative positioning for HCC?
• Which pipeline therapies do KOLs find the most promising and why?
• What will be the most significant changes to the HCC treatment paradigm over the next five years?

Key brands covered in this report:

Companies: